SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Acquired by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC lifted its position in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) by 41.4% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 116,915 shares of the company’s stock after buying an additional 34,260 shares during the period. Mutual of America Capital Management LLC owned 0.16% of SpringWorks Therapeutics worth $4,404,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of SWTX. Russell Investments Group Ltd. grew its holdings in SpringWorks Therapeutics by 49.0% in the 1st quarter. Russell Investments Group Ltd. now owns 170,047 shares of the company’s stock valued at $8,370,000 after buying an additional 55,893 shares during the period. Seven Eight Capital LP acquired a new position in SpringWorks Therapeutics during the fourth quarter worth approximately $1,544,000. Price T Rowe Associates Inc. MD raised its stake in SpringWorks Therapeutics by 48.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 4,110,462 shares of the company’s stock worth $202,318,000 after purchasing an additional 1,333,892 shares during the period. Perceptive Advisors LLC boosted its holdings in shares of SpringWorks Therapeutics by 28.7% in the 4th quarter. Perceptive Advisors LLC now owns 1,957,246 shares of the company’s stock valued at $71,439,000 after purchasing an additional 436,830 shares during the last quarter. Finally, Point72 Asset Management L.P. grew its stake in shares of SpringWorks Therapeutics by 310.7% during the 4th quarter. Point72 Asset Management L.P. now owns 2,162,176 shares of the company’s stock valued at $78,919,000 after buying an additional 1,635,722 shares during the period.

SpringWorks Therapeutics Price Performance

Shares of NASDAQ SWTX opened at $34.38 on Friday. The company has a market capitalization of $2.55 billion, a price-to-earnings ratio of -6.69 and a beta of 0.79. SpringWorks Therapeutics, Inc. has a 1-year low of $18.00 and a 1-year high of $53.92. The business has a 50-day moving average of $37.80 and a 200-day moving average of $41.32.

SpringWorks Therapeutics (NASDAQ:SWTX) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.12) by $0.58. The firm had revenue of $59.73 million during the quarter, compared to analyst estimates of $34.42 million. During the same period last year, the business earned ($1.25) EPS. The firm’s revenue was up 59732900.0% compared to the same quarter last year. Research analysts expect that SpringWorks Therapeutics, Inc. will post -3.36 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. JPMorgan Chase & Co. increased their target price on SpringWorks Therapeutics from $64.00 to $68.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 4th. Wedbush reaffirmed an “outperform” rating and issued a $77.00 price objective (up from $75.00) on shares of SpringWorks Therapeutics in a research note on Wednesday, August 28th. Finally, HC Wainwright reiterated a “buy” rating and set a $76.00 target price on shares of SpringWorks Therapeutics in a report on Wednesday, August 28th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, SpringWorks Therapeutics has a consensus rating of “Buy” and a consensus price target of $68.50.

SpringWorks Therapeutics Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.